GarcÃa-Alfonso, P.; Muñoz, A.; Jiménez-Castro, J.; Jiménez-Fonseca, P.; Pericay, C.; Longo-Muñoz, F.; Reyna-Fortes, C.; Argilés-MartÃnez, G.; González-Astorga, B.; Gómez-Reina, M.J.;
et al. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers 2021, 13, 4514.
https://doi.org/10.3390/cancers13184514
AMA Style
GarcÃa-Alfonso P, Muñoz A, Jiménez-Castro J, Jiménez-Fonseca P, Pericay C, Longo-Muñoz F, Reyna-Fortes C, Argilés-MartÃnez G, González-Astorga B, Gómez-Reina MJ,
et al. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers. 2021; 13(18):4514.
https://doi.org/10.3390/cancers13184514
Chicago/Turabian Style
GarcÃa-Alfonso, Pilar, Andrés Muñoz, Jerónimo Jiménez-Castro, Paula Jiménez-Fonseca, Carles Pericay, Federico Longo-Muñoz, Carmen Reyna-Fortes, Guillem Argilés-MartÃnez, Beatriz González-Astorga, MarÃa José Gómez-Reina,
and et al. 2021. "Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study" Cancers 13, no. 18: 4514.
https://doi.org/10.3390/cancers13184514
APA Style
GarcÃa-Alfonso, P., Muñoz, A., Jiménez-Castro, J., Jiménez-Fonseca, P., Pericay, C., Longo-Muñoz, F., Reyna-Fortes, C., Argilés-MartÃnez, G., González-Astorga, B., Gómez-Reina, M. J., Ruiz-Casado, A., RodrÃguez-Salas, N., López-López, R., Carmona-Bayonas, A., Conde-Herrero, V., Aranda, E., & on behalf of the ROS Study Group.
(2021). Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers, 13(18), 4514.
https://doi.org/10.3390/cancers13184514
